Mortality and associated factors in post-stem cell transplant patients: a two-year cohort in a public hospital in Peru.

IF 1.1 Q3 Medicine
Mario Agramonte-Vilca, Karol Moscol-Chavez, Lourdes Aranda-Gomero, Alfredo Wong-Chang, Stalin Vilcarromero, Cesar Copaja-Corzo
{"title":"Mortality and associated factors in post-stem cell transplant patients: a two-year cohort in a public hospital in Peru.","authors":"Mario Agramonte-Vilca, Karol Moscol-Chavez, Lourdes Aranda-Gomero, Alfredo Wong-Chang, Stalin Vilcarromero, Cesar Copaja-Corzo","doi":"10.17843/rpmesp.2025.423.14389","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective.: </strong>To determine mortality and associated factors in patients who received an allogeneic hematopoietic stem cell transplant at the Hospital Nacional Edgardo Rebagliati Martins, between January 2017 and December 2022.</p><p><strong>Materials and methods.: </strong>A retrospective cohort study was conducted on patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between 2017 and 2022. Death at one hundred days and two years, and its associated factors, were evaluated. Proportional Cox regression models were used.</p><p><strong>Results.: </strong>342 post-HSCT patients were included, with a median age of 23 years (interquartile range: 10 to 39), of whom 53.5% were women. The most frequent diagnosis for the transplant was acute lymphoblastic leukemia at 54.1%. Mortality in the first 100 days post-HSCT was 8.2%, and at two years was 30.4%. In the multivariate regression at one hundred days, factors associated with a higher risk of mortality were age over 50 years (HRa: 6.97; 95% CI: 1.18-41.23), being a recipient of a haploidentical transplant (HRa: 3.57; 95% CI: 1.13-11.24), and sepsis as a complication (HRa: 68.78; 95% CI: 19.32-244.84). In the two-year analysis, acute myeloid leukemia (1.72; IC 95%: 1.08-2.74), haploidentical transplant (HRa:1.81; 95%CI: 1.21-2.72), and disease relapse (HRa: 4.17; 95%CI%: 2.75-6.31) were associated with a higher risk of death.</p><p><strong>Conclusions.: </strong>The mortality found was low and similar to that of countries with higher incomes; however, it is necessary to formulate interventions that reduce the incidence of modifiable factors such as sepsis.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"42 3","pages":"252-262"},"PeriodicalIF":1.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12679968/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Peruana de Medicina de Experimental y Salud Publica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17843/rpmesp.2025.423.14389","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective.: To determine mortality and associated factors in patients who received an allogeneic hematopoietic stem cell transplant at the Hospital Nacional Edgardo Rebagliati Martins, between January 2017 and December 2022.

Materials and methods.: A retrospective cohort study was conducted on patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between 2017 and 2022. Death at one hundred days and two years, and its associated factors, were evaluated. Proportional Cox regression models were used.

Results.: 342 post-HSCT patients were included, with a median age of 23 years (interquartile range: 10 to 39), of whom 53.5% were women. The most frequent diagnosis for the transplant was acute lymphoblastic leukemia at 54.1%. Mortality in the first 100 days post-HSCT was 8.2%, and at two years was 30.4%. In the multivariate regression at one hundred days, factors associated with a higher risk of mortality were age over 50 years (HRa: 6.97; 95% CI: 1.18-41.23), being a recipient of a haploidentical transplant (HRa: 3.57; 95% CI: 1.13-11.24), and sepsis as a complication (HRa: 68.78; 95% CI: 19.32-244.84). In the two-year analysis, acute myeloid leukemia (1.72; IC 95%: 1.08-2.74), haploidentical transplant (HRa:1.81; 95%CI: 1.21-2.72), and disease relapse (HRa: 4.17; 95%CI%: 2.75-6.31) were associated with a higher risk of death.

Conclusions.: The mortality found was low and similar to that of countries with higher incomes; however, it is necessary to formulate interventions that reduce the incidence of modifiable factors such as sepsis.

Abstract Image

Abstract Image

干细胞移植后患者的死亡率及相关因素:秘鲁一家公立医院的两年队列研究
目标。目的:确定2017年1月至2022年12月期间在Edgardo Rebagliati Martins医院接受同种异体造血干细胞移植的患者的死亡率和相关因素。材料和方法。对2017年至2022年接受同种异体造血干细胞移植(HSCT)的患者进行回顾性队列研究。评估100天和2岁时的死亡情况及其相关因素。结果:纳入342例hsct后患者,中位年龄为23岁(四分位数范围:10 ~ 39),其中53.5%为女性。移植最常见的诊断是急性淋巴细胞白血病,占54.1%。移植后100天的死亡率为8.2%,两年后的死亡率为30.4%。在100天的多变量回归中,与死亡风险较高相关的因素是年龄超过50岁(HRa: 6.97; 95% CI: 1.18-41.23),接受单倍体移植(HRa: 3.57; 95% CI: 1.13-11.24),败血症作为并发症(HRa: 68.78; 95% CI: 19.32-244.84)。在为期两年的分析中,急性髓系白血病(1.72,IC 95%: 1.08-2.74)、单倍体移植(HRa:1.81, 95% ci: 1.21-2.72)和疾病复发(HRa: 4.17, 95% ci %: 2.75-6.31)与较高的死亡风险相关。结论:发现死亡率较低,与高收入国家相似;然而,有必要制定干预措施,以减少脓毒症等可改变因素的发生率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revista Peruana de Medicina de Experimental y Salud Publica
Revista Peruana de Medicina de Experimental y Salud Publica Medicine-Public Health, Environmental and Occupational Health
CiteScore
3.00
自引率
0.00%
发文量
57
审稿时长
12 weeks
期刊介绍: La Revista Peruana de Medicina Experimental y Salud Pública (RPMESP) es el órgano oficial de difusión científica del Instituto Nacional de Salud (INS) del Perú. Es una publicación arbitrada por pares, de periodicidad trimestral, de ámbito y difusión mundial, indizada en MEDLINE/Index Medicos, SCOPUS, EMBASE, SciELO Salud Pública y otras bases de datos internacionales. La RPMESP es distribuida en su versión impresa y electrónica, con acceso gratuito a texto completo. La RPMESP publica artículos referidos a temas del ámbito biomédico y de salud pública, resaltando aportes prácticos, que contribuyan a mejorar la situación de salud del país y de la región. Propicia el intercambio de la experiencia científica en salud entre instituciones y personas dedicadas a la investigación dentro y fuera del Perú a fin de promover el avance y la aplicación de la investigación en salud.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书